— Why it moved
Why SLXN Stock Popped and Collapsed Today — September 29, 2026
Silexion Therapeutics teased preclinical cancer data, but a massive warrant exercise deal at twenty-six cents sank the stock before regular hours even got underway.
What moved SLXN stock
Silexion Therapeutics is a clinical-stage oncology biotech working on targeted RNA therapies for KRAS-driven cancers. They announced positive preclinical findings for their SIL204 candidate showing natural uptake in tumor cells without synthetic carriers. Simultaneously, the company agreed to slash existing warrant exercise prices down to $0.2603 to raise immediate cash.
The mechanics
With a low float of 5.55 million shares and a micro-cap valuation under $1.4 million, the news sparked an 85% premarket gap. However, trading 249 million shares on massive warrant dilution quickly swallowed the small float.
SLXN by the numbers
The alert window
The alert went out at $0.4637 at 7:10 AM. It offered a tight eight-minute window to a peak of $0.5099 for a 10.0% gain, taking a brief 1.6% dip first. You had fourteen total minutes above the alert price before the move died completely.
How SLXN's move ended
By the session's close, the stock fell to $0.319, down 31.2% from the alert price. Discounted warrant exercises and millions of new warrants issued to raise $837k in cash crushed any early premarket momentum.
The tell: When a micro-cap pairs a clinical headline with a discounted warrant repricing, the immediate dilution always wins.